BIIB093

DRUG2 trials

Sponsors

Remedy Pharmaceuticals, Inc.

Conditions

Brain ContusionBrain EdemaStroke, Acute

Phase 2

A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion

TerminatedNCT03954041

Remedy Pharmaceuticals, Inc.Brain Contusion

Start: 2019-10-06End: 2023-06-27Updated: 2024-11-27

Phase 3

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

TerminatedNCT02864953

Remedy Pharmaceuticals, Inc.Brain Edema, Stroke, Acute

Start: 2018-08-29End: 2023-08-18Updated: 2024-11-25

Related Papers

Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.

2024-12-0113 citations

Diversity, Equity, and Inclusion in Local Clinical Trials (P5-9.004)

Neurology2023-04-25

Abstract TP20: Intravenous Glibenclamide For Large Hemispheric Infarction: Baseline Data From Initial Enrollees In The Charm Phase 3 Study

Stroke2022-02-011 citations

Use of Diffusion-Weighted Imaging-Alberta Stroke Program Early Computed Tomography Score (DWI-ASPECTS) and Ischemic Core Volume to Determine the Malignant Profile in Acute Stroke.

2019-11-0844 citations